Company news
Paradigm Biopharmaceuticals Ltd. news in 2017
Paradigm Biopharmaceuticals Ltd.'s news releases, calls and decks from 2017, newest first.
Paradigms Two Arthritis Phase 2 Clinical Trials on Schedule
November 22, 2017
Paradigms ACL Phase 2 Clinical Trial Success
November 13, 2017
PAR Successfully Completes A$5.75m Placement
November 5, 2017
First Participant Dosed in PARs Phase 2b OA Clinical Trial
October 29, 2017
PAR reports pain reduction in 83% of osteoarthritis patients
October 9, 2017
PARs Osteoarthritis Phase 2 Receives Ethics Approval
September 18, 2017
Paradigm Phase 2 Ross River Virus Clinical Trial Update
September 13, 2017
A Paradigm shift in treating osteoarthritis pain
September 10, 2017
Appendix 4E and 2017 Annual Report
August 29, 2017
Paradigm (PAR) - First Ross River Trial Participant Treated
August 8, 2017
Paradigm To Commence Phase 2 Ross River Virus Clinical Trial
July 9, 2017
Paradigm Enters Heart Failure Market
June 19, 2017
Hay Fever Trial Update
June 15, 2017
Paradigm Receives Ethics Approval for Ross River Trial
May 21, 2017
Paradigms preclinical hay fever trial published
May 15, 2017
Paradigm Government grant for Ross River virus research
May 10, 2017
Paradigm March Quarter Update & Appendix 4C
April 27, 2017
Final participant treated in Phase 2 hay fever trial
March 22, 2017
Paradigm receives $1.34 million R&D tax incentive rebate
March 21, 2017
Paradigm Update Ross River Virus Clinical Trial
March 7, 2017
Quarterly Cashflow Report
January 31, 2017
Recruitment complete in Paradigms hay fever clinical trial
January 24, 2017
Decks in 2017
- Investor Presentation (November 2017)
Investor deck · 22 slides · Nov 2, 2017
- Non-Deal Roadshow (May 2017)
Roadshow · 24 slides · May 15, 2017